As per DelveInsight, in 2020, the Crohn’s Disease prevalence in the United States was approximately 825,165, which is expected to increase steadily in the coming decade. People of any age can be affected with Crohn’s disease, however, it is often diagnosed in the population of age group 20-30.
The present Crohn’s disease market reluctantly relies on the available biologics, mainly anti-tumor necrosis factor (anti-TNF) therapies such as Entyvio (Vedolizumab), Certolizumab pegol, Natalizumab, Humira (adalimumab), and Stelara (Ustekinumab), and others. Crohn’s Disease Market is expected to expand modestly owing to the continuous research and developments activities and innovation in drug delivery platforms, MoAs, and RoAs.
Some of the key pharmaceutical companies developing novel therapies to combat the unmet needs prevailing in the Crohn’s Disease Therapeutics Market include Eli Lilly, RedHill Biopharma Ltd., AbbVie, and Boehringer Ingelheim, Gilead Sciences, Galapagos, Celgene, The Janssen Pharmaceutical Companies of Johnson & Johnson, among several others. In the coming years, a better understanding and awareness of the disease, the rise in Crohn’s disease prevalence, and the influx of key pharma and biotech companies in the therapeutics domain are expected to expand the market growth positively.
For more details, visit: Crohn's Disease Therapeutic Pipeline